Cat. #160706
Mitochondrial complex II mutated SDHD cell line
Cat. #: 160706
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 10-12 weeks
Organism: Human
Disease: Mitochondrial Disease
Model: Knock-Out
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Abey Bandara
Institute: Virginia Tech
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Mitochondrial complex II mutated SDHD cell line
- Alternate name: HEK293?SDHD
- Research fields: Cancer;Drug development;Metabolism
- Tool sub type: Continuous
- Parental cell: HEK293
- Organism: Human
- Disease: Mitochondrial Disease
- Growth properties: The mutant has been shown to grow much slower than the parental cell line. The doubling time of the mutant is also significantly slower than that of the parental line.
- Model: Knock-Out
- Description: The HEK293?SDHD cell line expresses a CRISPR/Cas9 mutated nuclear encoded subunit, SDHD, of mitochondrial complex II (succinate dehydrogenase). This cell line has been shown to significantly alter the function of complex II (CII) of the mitochondrial electron transport chain and displays disruptions to SDHD that mimic clinical presentations of CII deficiency. These cells represent a powerful model of metabolic pathologies, not only for mitochondrial disease, but also for understanding the importance of CII in developing novel therapeutics. CRISPR edited HEK293 cells.Specific disruptions in SDHD have been reported to present clinically as the following disease conditions:-Complex II deficiency-Paraganglioma
- Production details: The cell line is currently stored at Virginia Tech.
- Additional notes: CRISPR edited HEK293 cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provi...
- Recommended controls: HEK293 parental line
Target Details
- Target: SDHD
Applications
- Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to comp...
Handling
- Format: Frozen
- Growth medium: DMEM medium supplemented with 10% Fetal Bovine Serum and 1% Penicillin-Streptomycin at 37?°C temperature and 5-6% CO2.
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
Related Tools
- Related tools: HEK293?NDUFS2 Cell Line
References
- Bandara et al. 2021. BMC Mol Cell Biol. 22(1):35. PMID: 34118887.
